Biller worked previously as vice president and head of global discovery chemistry at the Novartis Institutes for BioMedical Research (NIBR), where he oversaw the research metabolism and pharmacokinetics groups, in addition to medicinal, combinatorial and computational chemistry. Before joining Novartis in 2003, Biller served as vice president, pharmaceutical candidate optimization, at the Bristol Myers Squibb Pharmaceutical Research Institute and executive director of drug discovery chemistry for the BMS research site in Lawrenceville, N.J.

Agios Pharmaceuticals was founded by cell metabolism leaders Lewis C. Cantley, director of the Cancer Center at Beth Israel Deaconess Medical Center and professor of systems biology at Harvard Medical School; Tak W. Mak, of The Campbell Family Institute for Cancer Research and The University of Toronto; and Craig B. Thompson, director of the Abramson Cancer Center, University of Pennsylvania.